Beauty Health Company, popularly known by the ticker symbol SKIN, is a leading innovator in the aesthetic health and wellness industry based in Long Beach, California. SKIN is renowned for pioneering technological advancements in skincare and wellness solutions.
The company is the manufacturer behind the famous HydraFacial, a non-invasive skin treatment that cleanses, extracts and hydrates the skin. The treatment employs proprietary serums, infused with a mix of hydrating ingredients and antioxidants, which are tailored to each client's specific skincare needs. Unlike traditional facials, HydraFacial uses vacuum technology to deliver these serums, promoting a deeper absorption to enhance the overall skin health and aesthetics.
Beauty Health Co emphasizes a personalized approach to skincare, considering the unique characteristics and needs of every client's skin. Its flagship product, HydraFacial, is designed to be adaptable, accommodating different skin types and addressing a broad spectrum of skin concerns such as fine lines, wrinkles, skin tone unevenness, oily skin, and congested pores.
The company takes pride in its role as a change-maker in the skincare industry and it continues to push boundaries through enhancing the HydraFacial experience. It collaborates with top-notch research institutes and dermatologists to ensure scientific accuracy and effectiveness. As a result, it has managed to create a community of loyal clients globally, including skincare professionals and celebrities.
On the business side, Beauty Health Co went public through a merger with special-purpose acquisition corporation (SPAC) Vesper Healthcare Acquisition Corp in May 2021, listing on Nasdaq under the ticker symbol SKIN. The company has experienced tremendous and above average growth, which is attributed to its innovative products, excellent customer service, and effective growth strategies.
Beauty Health Co is guided by its mission to provide immediate and long-lasting skincare results to people all over the world. By offering deep skin health restoration and protection, the company holds true its belief that everyone deserves to feel good and confident in their own skin.
Staying true to its humanitarian values, the company also works to empower the people by providing education about skin health and self-care. Through its initiatives, SKIN is playing a significant role in shaping the skincare industry to be more inclusive, comprehensive, and efficient in addressing individual skincare needs and concerns.
In summary, Beauty Health Co (SKIN) is the hallmark of aesthetic beauty and wellness solutions distinguished by its innovative treatment, HydraFacial, and its commitment to providing personalized skincare treatments. The company continually invests in research and development to enhance the efficacy of its skincare treatments, maintain its market leadership, and ultimately, bolster the trust and loyalty of its consumer base.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
The Beauty Health Company (NASDAQ:SKIN) has received a consensus "Hold" rating from seven analysts, with an average 12-month price target of $1.375. Despite recent reductions in outlook from some firms, Roth Capital reaffirmed a "buy" rating. The company's stock opened at $0.69, near its 52-week low, and reported quarterly revenue below expectations with a loss of $0.02 per share.
Beauty Health (SKIN) received a Nasdaq notice on May 8, 2026, due to its stock trading below $1.00 for 30 consecutive business days, violating the exchange's minimum bid price rule. The company has until November 4, 2026, to regain compliance, with possible recourse to measures like a reverse stock split. This situation signals an elevated delisting risk for the company's shares.
Beauty Health (NASDAQ:SKIN) reported Q1 EPS of -$0.05, surpassing analyst estimates by $0.04, though revenue of $64.91 million fell short. The company revised its full-year revenue outlook downwards due to weaker device placements but maintained its full-year adjusted EBITDA guidance. Shares traded down 36.3% following the announcement, reflecting market concerns despite improved adjusted EBITDA and lower churn rates.
The Beauty Health Company, rebranded as SkinHealth Systems, reported Q1 2026 revenue of $64.9 million, meeting guidance, though device placements underperformed. Adjusted EBITDA significantly exceeded expectations at $8.5 million due to higher Americas selling prices and operational efficiency. The company refined its full-year revenue outlook downwards but maintained EBITDA guidance, projecting a return to growth in 2027 and a next-generation Hydrafacial launch in 2028.
The Beauty Health Company (NASDAQ:SKIN) has an average "Hold" rating from eight analysts, with an average 12-month price target of $2.32. Despite reporting quarterly earnings that beat estimates, the company remains unprofitable with negative return on equity. Institutional investors hold approximately 93.26% of the stock.